
-
Tarsus Pharmaceuticals NasdaqGS:TARS Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Location: 15440 Laguna Canyon Road, Irvine, CA, 92618, United States | Website: https://www.tarsusrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.49B
Cash
407.9M
Avg Qtr Burn
-16.47M
Short % of Float
23.81%
Insider Ownership
3.23%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XDEMVY (TP-03) Details Eye disease , Demodex Blepharitis | Approved Quarterly sales | |
TP-03 Details Meibomian Gland Disease , Demodex Blepharitis | Phase 3 Update | |
TP-04 Details Ocular Rosacea | Phase 2 Initiation | |
TP-05 Details Lyme disease | Phase 2a Update | |
TP-04 Details Papulopustular rosacea | Phase 2a Update | |
TP-03 Details Meibomian Gland Disease | Phase 2a Update |